Elvucitabine

Drug Profile

Elvucitabine

Alternative Names: ACH-126443; Beta-L-Fd4C; Beta-LFD4C; FD4C-beta-L

Latest Information Update: 29 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Achillion Pharmaceuticals
  • Class Antivirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Hepatitis B; HIV infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Feb 2014 Suspended - Phase-II for HIV infections (Combination therapy, Treatment-naive) in Puerto Rico (PO)
  • 20 Feb 2013 Suspended - Phase-II for Hepatitis B in USA, Canada, Eastern Europe and Central Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top